A recent study evaluating the potential of A. paniculata as an immunostimulant for COVID-19 patients using a combination synergy analysis, based on network pharmacology, suggested that the compounds in A. paniculata possessed immune-protective and antiviral properties via different pathways, including the toll-like receptor pathway, the PI3/AKT pathway, and the MAP kinase pathways, which could offer benefits against SARS-CoV-2 and upper respiratory tract infections [133]. Here, AKT1 is linked to Recurrent upper respiratory tract infections.